News
Market and company headlines
EXELAll
Loading
08:00-14:00Oct 232 Stories
BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.
Oncology-focused biotech firm BeOne Medicines explores buy zone, boosted by strong demand and stellar earnings growth.
Exelixis Rises with Earnings on Tap
Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017.
05:00Oct 231 Story
09:00Oct 221 Story
05:00Oct 191 Story
11:00-17:00Oct 152 Stories
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
ALAMEDA, Calif., October 15, 2026--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company’s website.
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
08:00Oct 121 Story
06:00Oct 91 Story
05:00-07:00Oct 82 Stories
RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45
RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lowers the price target from $46 to $45.
Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?
Exelixis (EXEL) is drawing attention after a year of strong share performance. The stock is up about 51% over the past 12 months and roughly 171% over three years. Recent trading in Exelixis has been relatively steady, with the share price at US$58.44 and short term moves broadly flat. However, the 1 year total shareholder return of 51.24% and 3 year total shareholder return of 171.81% indicate momentum that has built over time rather than faded. Scan other oncology and biotech players...